Lifeline for myeloma patients: study extends access to promising drug

NCT ID NCT02719613

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This study offers continued treatment with elotuzumab and other drugs to 67 multiple myeloma patients who were already benefiting from these therapies in earlier trials but cannot yet get the drug commercially. The main goal is to track how long patients stay on treatment and monitor any serious side effects. It is not a cure, but aims to keep the disease under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Bethlehem, Pennsylvania, 18015, United States
Local Institution - 0002

Boston, Massachusetts, 02215, United States
Local Institution - 0003

Indianapolis, Indiana, 46260, United States
Local Institution - 0004

New York, New York, 10029, United States
Local Institution - 0008

St Louis, Missouri, 63110, United States
Local Institution - 0009

Atlanta, Georgia, 30322, United States
Local Institution - 0010

Halifax, B3H 2Y9, Canada
Local Institution - 0011

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0012

Florence, 50134, Italy
Local Institution - 0013

Genova, 16132, Italy
Local Institution - 0014

Torino, 10126, Italy
Local Institution - 0015

Ancona, 60126, Italy
Local Institution - 0016

West Hollywood, California, 90069, United States
Local Institution - 0017

Bakersfield, California, 93309, United States
Local Institution - 0018

Dallas, Texas, 75231, United States
Local Institution - 0019

Denver, Colorado, 80218, United States
Local Institution - 0020

Tucson, Arizona, 85715, United States
Local Institution - 0021

Jacksonville, Florida, 32256, United States
Local Institution - 0022

Fountain Valley, California, 92708, United States
Local Institution - 0023

Antwerp, 2060, Belgium
Local Institution - 0026

Warsaw, 02-106, Poland
Local Institution - 0027

Chorzów, 41-500, Poland
Local Institution - 0028

Bucharest, 030171, Romania
Local Institution - 0029

Iași, 700483, Romania
Local Institution - 0030

Toledo, 45004, Spain
Local Institution - 0031

Cebeci Ankara, 06620, Turkey (Türkiye)
Local Institution - 0032

London, EC1A 7BE, United Kingdom
Local Institution - 0034

Heidelberg, Victoria, 3084, Australia
Local Institution - 0035

Athens, 11528, Greece
Local Institution - 0036

Budapest, 1097, Hungary
Local Institution - 0039

Warsaw, 02-776, Poland
Local Institution - 0041

Barcelona, 08036, Spain
Local Institution - 0042

St. Petersburg, Florida, 33705, United States
Local Institution - 0043

Ravenna, 48121, Italy
Local Institution - 0044

Terni, 05100, Italy
Local Institution - 0045

Kasama-shi, 3091793, Japan
Local Institution - 0046

Aomori, Aomori, 0308553, Japan
Local Institution - 0047

Shibukawa-shi, Gunma, 3770280, Japan
Local Institution - 0048

Koto-ku, Tokyo, 135-8550, Japan
Local Institution - 0049

Osaka, Osaka, 5300012, Japan
Local Institution - 0050

Chiba, 260-8677, Japan

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA